People
The move was announced due to the advisor’s role in overseeing a clinical study for Moderna’s mRNA vaccine candidate.
Competition for resources is growing, and the usual supply chain partners may not have available capacity in the preferred timeframe.
Last week, HHS Secretary Alex Azar assumed all final authority in deciding new rules regarding food, medical devices and new medications.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Cidara Therapeutics is hoping that its novel approach to influenza will prevent future “twindemic” double threats like the one we may face this year.
Robert Redfield, director of the U.S. Centers for Disease Control and Prevention, testified yesterday before the U.S. Senate Appropriations subcommittee on labor, health and human services, education and related agencies.
The study, led by U.S. researchers, showed that the novel system was safe and effective for managing blood glucose in children as young as 6 years old.
One company working towards an ARDS treatment is Athersys, a biotech company focusing on regenerative medicine therapies for diseases with significant unmet need.
Although it is increasingly likely that one of the COVID-19 vaccines currently being tested will be approved or receive Emergency Use Authorization before the end of the year, experts are increasingly warning that widespread distribution may take a much longer time.
The company is genetically programming RNA not just to deliver a gene of interest, but to control the location, timing and intensity of therapeutic protein expression using mRNA-encoded logic circuits.
PRESS RELEASES